ArticleCureus2025
Therapy-Related Toxicity in Bladder Cancer Treatment: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a commonly diagnosed cancer worldwide. Within muscle-invasive bladder cancer (MIBC), the disease may present as localized or as metastatic. MIBC requires distinct therapeutic approaches, ranging from local treatments for preventing recurrence to systemic therapy. In this case report, we present the clinical case of a 67-year-old man diagnosed with muscle-invasive urothelial bladder cancer. His treatment through different stages of the disease is described, with the inclusion of immunotherapy-related toxicity. This case illustrates the complex treatment landscape for advanced MIBC, for which curative-intended strategies are standard, but disease relapse frequently occurs. The relevance of individualized treatment is highlighted. Advances in immunotherapy and the use of targeted therapy and antibody-drug conjugates provide hope for improved outcomes, but careful and often multidisciplinary management of treatment-related complications remains critical for optimizing patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.